SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 25.23 |
Enterprise Value ($M) | 14.02 |
Book Value ($M) | -6.01 |
Book Value / Share | -0.69 |
Price / Book | -4.20 |
NCAV ($M) | -9.67 |
NCAV / Share | -1.11 |
Price / NCAV | -2.61 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | -0.31 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.85 |
Current Ratio | 0.85 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 18.45 |
Assets | 22.10 |
Liabilities | 28.11 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.01 |
Operating Income | -23.45 |
Net Income | -4.05 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 5.39 |
Cash from Investing | -0.57 |
Cash from Financing | 0.43 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
2,232 | 7,874 | 28.35 | |
3,113 | 28,096 | 11.08 | |
5,342 | 19,268 | 27.72 | |
860 | 8,008 | 10.74 | |
(click for more detail) |
Similar Companies | |
---|---|
CYCC – Cyclacel Pharmaceuticals, Inc. | CYCN – Cyclerion Therapeutics, Inc. |
CYRX – Cryoport, Inc. | DERM – Journey Medical Corporation |
DMAC – DiaMedica Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io